Relugolix Fails to Delay Castration Resistance in Advanced PC, Trial Shows

Relugolix Fails to Delay Castration Resistance in Advanced PC, Trial Shows
Relugolix, a form of hormone therapy for prostate cancer, has failed to significantly extend the time men with advanced disease live without acquiring resistance to castration medications, compared with standard-of-care leuprolide acetate, updated findings from the HERO trial show. While the trial (NCT03085095) had met its primary goal of increasing the proportion of patients achieving sustained testosterone reduction through 48 weeks, along with several other secondary endpoints, it now failed to demonstrate the benefits of relugolix in this additional secondary measure. “These new data from the Phase 3 HERO study show that three out of four men with metastatic prostate cancer remained castration resistance-free through 48 weeks while on oral relugolix, in-line with leuprolide acetate injections, the current standard of care,” Dan George, MD, a professor at the Duke University School of Medicine, said in a press release. “I continue to be excited by relugolix as a potential new and differentiated treatment option for men with prostate cancer given its robust clinical and safety data, including the lower risk of major adverse cardiovascular events compared to leuprolide acetate
Subscribe or to access all post and page content.

Pin It on Pinterest

Share This